Yissum Ltd. to Collaborate with BioConnections for the Commercialization of Kits for Identifying Antibiotic Resistant Infections

Published: Feb 27, 2012

JERUSALEM--(BUSINESS WIRE)--Yissum, the research and development company of the Hebrew University of Jerusalem, had signed a licensing agreement with BioConnections, a UK based microbiology company, for the commercialization of kits that enables immediate detection of all multidrug resistant (MDR) and of any extremely drug resistant (XDR) infections. The kits are based on a novel method that was developed by Professor Emeritus Nathan Citri, from the Faculty of Medicine, The Hebrew University of Jerusalem. It enables direct and precise recognition of bacterial resistance to all members of the family of beta-lactams, which is the most widely used group of antibiotics, including penicillins, cephalosporins and carbapenems. Furthermore, the kits not only detect the presence of bacteria resistant to antibiotics, but also offer immediate information on the type of antibiotic that may still be of use.

Back to news